

Chromium

Fact Sheet for Health Professionals

Expand All

Consumer Datos en español

Health Professional

Other Resources

This is a fact sheet intended for health professionals. For a general overview, see our [consumer fact sheet](#).

Introduction

Chromium, as present in many foods, exists as hexavalent and other manufactured chromium.

Chromium might be a potentiating in its action. It has not been identified as an oligopeptide transport substance that

action [4,6-8]. Chromium might also have antioxidant effects [1].

In 2001, the Food and Nutrition Board (FNB) of the National Academies of Sciences, Engineering, and Medicine considered chromium to be an essential nutrient based on its effects on insulin action [2]. However, recent research has suggested that although chromium might have benefits at pharmacologic amounts (e.g., in the hundreds of mcg), it is not an essential mineral because an absence or deficiency of chromium does not produce abnormalities that can be reversed with the addition of chromium (see the Chromium Deficiency section below) [5,9-13]. The FNB has not evaluated chromium since 2001. However, in 2014, the European Food Safety Authority Panel on Dietetic Products, Nutrition



STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

Email Address

SUBSCRIBE

No Thanks

Remind Me Later

naturally
mium also
steel and
ely on trivalent

abolism by
or this activity
nds to an
m-binding
ote insulin

and Allergies concluded that no convincing evidence shows that chromium is an essential nutrient and, therefore, setting chromium intake recommendations would be inappropriate [5].

In the blood, most chromium is bound to plasma proteins, particularly transferrin, and only about 5% is unbound [5,12]. Chromium accumulates mainly in the liver, spleen, soft tissue, and bone [2,5,12].

Chromium is excreted mainly in the urine [1,12,13]. Urinary chromium levels are therefore a good indicator of chromium absorption. However, because these levels are closely related to recent chromium intakes, they are not good indicators of chromium body stores [4,14]. Hair levels might reflect past chromium intakes [5], and some studies have measured chromium levels in hair, sweat, serum, and toenails [15,16]. However, no validated methods for determining chromium status exist [6,8].

Recommendations

Intake recommendations are provided in the Dietary Reference Intakes (DRI) at the National Academies Press. The general term for the recommended nutrient intake is the Recommended Dietary Allowance (RDA), which includes the following:

- Recommended Dietary Allowance (RDA): The average daily level of intake sufficient to meet the requirements of nearly all (97%–98%) healthy individuals; often used to plan nutritionally adequate diets for individuals
- Adequate Intake (AI): Intake at this level is assumed to ensure nutritional adequacy; established when evidence is insufficient to develop an RDA
- Estimated Average Requirement (EAR): Average daily level of intake estimated to meet the requirements of 50% of healthy individuals; usually used to assess the nutrient intakes of groups of people and to plan nutritionally adequate diets for them; can also be used to assess the nutrient intakes of individuals
- Tolerable Upper Intake Level (UL): Maximum daily intake unlikely to cause adverse health effects



STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

In its 2001 evaluation, the FNB found the existing data insufficient to derive an EAR for chromium. The FNB therefore established AIs for all ages based on usual chromium intakes in healthy populations [2]. Table 1 lists the current AIs for chromium.

Table 1: Adequate Intakes (AIs) for Chromium [2]

Age	Male	Female	Pregnancy	Lactation
Birth to 6 months*	0.2 mcg	0.2 mcg		
7–12 months*	5.5 mcg	5.5 mcg		
1–3 years	11 mcg	11 mcg		
4–8 years	15 mcg	15 mcg		
9–13 years	25 mcg	21 mcg		
14–18 years	35 mcg	24 mcg	29 mcg	44 mcg
19–50 years				
51+ years				

[Download this table](#)

*For infants from birth to 12 months, the mean chromium intake from breast milk and complementary feeding is 0.2 mcg.

Sources of Chromium

Food

Chromium is present in a variety of foods, including grains, fruits, vegetables, nuts, and dairy products. Chromium amounts in these foods vary widely depending on local soil and water conditions as well as agricultural and manufacturing processes used to produce them [4,7,12,17-20]. For example, the amount of chromium can vary 50-fold in samples of oatmeal because of growing and processing differences [21]. Some chromium can also be transferred to foods from stainless steel equipment during food processing and from pots and pans during cooking [3,4,10,17,20,22,23].

Most dairy products and foods high in sugar (e.g., sucrose and fructose) are low in chromium [2,17,24].



STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

Human milk contains about 0.25 mcg/L chromium [2], but reported values vary widely. Small studies in Europe found chromium concentrations ranging from 0.14 to 10.8 mcg/L [5].

Dietary chromium absorption is low, ranging from about 0.4% to 2.5% [5,6]. Ascorbic acid and prostaglandin inhibitors, such as aspirin, increase chromium absorption, whereas oxalate and antacids inhibit it [1,22,25].

A variety of types of foods and their chromium levels per serving are listed in Table 2. Determining the chromium content of food is challenging because samples are easily contaminated by standard tools used for measurement and analysis [2]. Therefore, the values in Table 2 should only serve as a guide.

Table 2: Chromium Content of Selected Foods [17,19]

Food	Micrograms	
	per serving	per 100 g
Grape juice, 1 cup	0.1	0.1
Ham, 3 ounces	0.1	0.1
English muffin, 1	0.1	0.1
Brewer's yeast, 1	0.1	0.1
Orange juice, 1 cup	0.1	0.1
Beef, 3 ounces	0.1	0.1
Lettuce, 1 wedge	0.1	0.1
Turkey breast, 3	0.1	0.1
Barbecue sauce, 1	0.1	0.1
Tomato juice, 1	0.1	0.1
Apple, with peel, 1 medium	1.4	4
Green beans, ½ cup	1.1	3
Banana, 1 medium	1.0	3
Whole wheat bread, 1 slice	1.0	3
Ketchup, 1 tablespoon	1.0	3
Tomato, 1 medium	0.9	3
American cheese, 1½ ounces	0.8	2
Peanut butter, 1 tablespoon	0.6	2
Rice, white, ½ cup	0.6	2
Haddock, 3 ounces	0.6	2

Food	Micrograms (mcg) per serving	Percent DV*
Chicken breast, 3 ounces	0.5	1
Peas, ½ cup	0.4	1
Orange, 1 medium	0.4	1
Spaghetti, 1 cup	0.3	1
Carrots, raw, 1 medium	0.3	1
Egg, 1 medium	0.2	1
Celery, 1 stalk	0.1	0
Fat free milk, 1 cup	<0.1	0

[Download this table as a CSV file](#)

*DV = Daily Value. The DVs are intended to help consumers understand the relative amounts of nutrients in dietary supplements versus foods. The DVs are for adults and children aged 14 years and older. The DV for chromium is 35 mcg. The DVs are based on a diet providing 20% of the DV for each nutrient, but foods provide a much smaller amount of a nutrient, a healthy diet.

Dietary supplements

Most multivitamin supplements contain 35–120 mcg. Supplemental chromium is commonly provided in doses of 1,000 mcg [16,27].

Dietary supplements contain many forms of chromium, including chromium picolinate, chromium nicotinate, chromium polynicotinate, chromium chloride, and chromium histidinate [18,27]. The absorption of various forms of chromium is similar [6,9]. For example, research suggests that the proportion of chromium absorbed from chromium picolinate is about 1.2%, whereas that from chromium chloride is about 0.4% [1]. These values are similar to the proportion of chromium absorbed from food [5].

Developed DVs for chromium. The DV for chromium is 35 mcg. The DVs are based on a diet providing 20% of the DV for each nutrient, but foods provide a much smaller amount of a nutrient, a healthy diet.

ly 35–120 mcg. Supplemental chromium is commonly provided in doses of 1,000 mcg [16,27].



National Institutes of Health
Office of Dietary Supplements

STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

Chromium compounds contain various percentages of elemental chromium. For example, elemental chromium accounts for 12.4% of the weight of chromium picolinate [18,28]. The Supplement Facts label on a dietary supplement product declares the amount of elemental chromium, not the weight of the entire chromium compound, in the product.

Chromium Intakes and Status

The National Health and Nutrition Examination Survey (NHANES) provides dietary intake data for many nutrients, but not chromium [29]. Therefore, data on chromium intakes in the United States are limited.

A small study in eight men and 11 women in the United States found mean chromium intakes of about 29 mcg/day for women and 54 mcg/day for men [30]. In another study, the mean chromium intake of 22 well-balanced diets ranged from about 17 to 47 mcg/day. Chromium intakes in the United States have changed over time, and a more recent assessment in 2001 found mean chromium intakes of about 57 mcg/day for women and 107 mcg/day for men.

Data on chromium status are limited. According to a 2001 study, the mean chromium intake of 22 well-balanced diets ranged from about 17 to 47 mcg/day. Chromium intakes in the United States have changed over time, and a more recent assessment in 2001 found mean chromium intakes of about 57 mcg/day for women and 107 mcg/day for men.

Chromium

Chromium deficiency has not been reported in healthy populations, and no definitive deficiency symptoms have been established [3,4].

In three case studies published in the 1970s and 1980s, patients on long-term total parenteral nutrition (TPN) experienced adverse metabolic and neurological effects, including hyperglycemia, glycosuria, unexplained weight loss, peripheral neuropathy, glucose intolerance, and/or confusion [32-34]. These effects were alleviated with pharmacologic amounts of chromium. Although these adverse effects were presumed to be caused by chromium deficiency, the studies did not adequately evaluate the chromium concentrations in the TPN solutions [5].



STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

Scientists have concluded, based on recent evaluations, that these studies do not provide evidence that the patients had chromium deficiency and thus do not demonstrate that healthy people can develop chromium deficiency [3,5,6,10,13].

Currently, chromium is routinely added to TPN solutions to provide 10–15 mcg chromium per day, a much higher daily amount than the approximately 0.15 mcg/day that healthy individuals absorb from a balanced diet [9]. Thus, the American Society for Parenteral and Enteral Nutrition and other experts recommend research on parenteral chromium requirements to determine whether chromium levels in TPN solutions should be lowered [9,13,35,36].

Chromium and Health

This section focuses on five conditions in which chromium might have beneficial effects: impaired glucose tolerance, type 2 diabetes, polycystic ovarian syndrome, obesity, and muscle mass.

Impaired glucose tolerance

Because chromium is a cofactor for insulin, researchers have examined whether increased chromium intake might improve impaired glucose tolerance.

Numerous randomized controlled trials have examined the effects of chromium supplements—ranging from 100 to 1,000 mcg (micrograms) per day—in people without diabetes. In a meta-analysis of 10 studies, researchers found that chromium supplementation had no significant effect on fasting glucose levels in people without diabetes [37]. One of the most common

supplementation for type 2 diabetes was a 1997 randomized controlled trial [37]. The trial assigned 180 adults age 35–65 years with type 2 diabetes to receive 100 mcg chromium (as chromium picolinate), 500 mcg chromium, or placebo twice daily for 4 months. At both 2 and 4 months, participants receiving 1,000 mcg/day chromium had significantly lower fasting serum glucose concentrations than those receiving placebo or 200 mcg/day chromium. At 4 months, for example, mean fasting serum glucose levels were 7.1 mmol/L (128 mg/dL) in the group receiving 1,000 mcg/day chromium and 8.8 mmol/L (159 mg/dL) in those receiving placebo. Mean serum glucose concentrations after a 75 g glucose challenge were also significantly lower at both 2 and 4 months in



STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

those receiving 1,000 mcg/day chromium (10.5 mmol/L [189 mg/dL] at 4 months vs. 12.3 mmol/L [222 mg/dL] for placebo). In comparison with placebo, both 200 mcg and 1,000 mcg/day chromium also significantly reduced fasting insulin concentrations at both 2 and 4 months, as well as insulin concentrations after a glucose challenge. Finally, hemoglobin A1c (HbA1c) levels were significantly lower after 4 months in participants receiving 200 mcg/day chromium (mean 7.5%) or 1,000 mcg/day chromium (mean 6.6%) than in those receiving placebo (mean 8.5%). HbA1c is a robust measure of blood glucose control because it reflects long-term changes in blood glucose levels [38].

Several subsequent studies that used various doses of chromium had inconsistent findings. A 2019 review of chromium and glycemic control included eight meta-analyses and systematic reviews of a total of 58 clinical trials [16].

The trials lasted from 2 weeks to 6 months and administered 1,28 to 1,000 mcg chromium daily. In a 2019 review, the authors concluded that chromium supplementation followed by year-long follow-up did not significantly affect fasting glucose and HbA1c levels. However, the authors noted that the studies were of low quality. The overall significance of these findings is uncertain. The authors concluded that chromium supplementation may be of benefit for people with type 2 diabetes, but more research is needed to confirm the insufficient evidence for chromium supplementation in people with type 2 diabetes to significantly lower blood glucose levels in healthy people.

Some research suggests that chromium supplementation may be beneficial for people with type 2 diabetes, but more research is needed. In a randomized trial in 137 participants age 30–70 years with type 2 diabetes, daily supplementation with 1,000 mcg chromium (as chromium picolinate) for 24 weeks did not significantly affect insulin sensitivity, fasting glucose levels, or HbA1c values in comparison with placebo [40]. However, some participants did respond to chromium supplementation, and these people had significantly lower insulin sensitivity (3.98 vs. 5.91 mg/kg fat-free mass/min) and higher fasting glucose (8.5 vs. 6.7 mmol/L [153 vs. 121 mg/dL]) and HbA1c levels (7.57 vs. 6.29%) than those who did not respond.

Manufacturers market chromium supplements widely in the United States for people with type 2 diabetes, and many adults use them in the hope that the



STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

supplements will reduce their risk of diabetes or improve their glycemic control [6,8,18,39]. However, FDA allows only the following qualified health claim for chromium picolinate dietary supplements:

“One small study suggests that chromium picolinate may reduce the risk of insulin resistance, and therefore possibly may reduce the risk of type 2 diabetes. FDA concludes, however, that the existence of such a relationship between chromium picolinate and either insulin resistance or type 2 diabetes is highly uncertain” [41,42].

In its 2010 diabetes guidelines, the American Diabetes Association concluded that because studies have not definitively shown that chromium supplementation benefits people with diabetes or obesity, the association cannot recommend such supplementation [43]. This determination was based

on conflicting evidence. Similarly, the association between chromium and insulin resistance is insufficient to recommend chromium and other micronutrient supplementation [44]. Additional research is needed in this background, and chromium supplementation might be more effective in certain populations (e.g., ethnic groups).



STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

Metabolic syndrome

Metabolic syndrome is a cluster of conditions that increase the risk of heart disease, diabetes, and stroke. These conditions include high blood pressure, high blood sugar, high triglyceride levels, low HDL cholesterol, and abdominal obesity.

Metabolic syndrome is a cluster of conditions that increase the risk of heart disease, diabetes, and stroke. These conditions include high blood pressure, high blood sugar, high triglyceride levels, low HDL cholesterol, and abdominal obesity. This condition and is a potential therapeutic target for dietary interventions for metabolic syndrome [46]. A prospective study of 3,648 adults age 20–32 years found that baseline toenail chromium concentrations were inversely associated with the incidence of metabolic syndrome over 23 years of follow-up [47]. For these reasons, some scientists have hypothesized that chromium supplements might benefit people with metabolic syndrome.

Only a few clinical trials of chromium supplementation for metabolic syndrome have been conducted [46,48-50]. One of these trials included 63 adults age 18 to 75 years with metabolic syndrome who received either 500 mcg chromium picolinate or placebo twice daily for 16 weeks [46]. In comparison with placebo,

chromium supplementation significantly increased acute insulin response to glucose but did not affect HbA1c levels, insulin sensitivity, or other measures of glucose metabolism. Chromium supplementation also had no effect on body weight or serum lipids.

Similarly, in a 2018 clinical trial of 70 adults (mean age 58 years) with metabolic syndrome and impaired glucose tolerance, daily supplementation with 300 mcg chromium (200 mcg with breakfast and 100 mcg with dinner, as chromium yeast) for 24 weeks did not affect fasting glucose levels, HbA1c, waist circumference, blood pressure, or lipid levels [49].

Overall, limited research suggests that chromium supplements do not significantly benefit people with metabolic syndrome.

Polycystic o

PCOS is a com
is characteriz
elevated risks
insulin resista
investigated th
maintain glyce

Four recent sy
have examine
PCOS [52,54-5
participants th
to 1,000 mcg c

effect on fasting blood glucose, total testosterone, dehydroepiandrosterone, follicle-stimulating hormone, or luteinizing hormone levels. However, chromium did significantly reduce body mass index (BMI) by 2.37 kg/m² and free testosterone levels by 0.52 pg/mL in comparison with placebo; it also significantly reduced fasting insulin levels by 0.33 milli-IU/mL.

Another systematic review and meta-analysis of five randomized trials lasting 8 weeks to 6 months that included a total of 268 women with PCOS compared supplemental chromium (200–1,000 mcg/d, mostly as chromium picolinate) with placebo or metformin [55]. Chromium supplementation had no significant effect on fasting insulin levels or insulin sensitivity, but data from two trials



STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

active age. It
ism, and
]. Because
ave
S to help

clinical trials
symptoms of
351
at 200 mcg
ion had no

showed that it did significantly lower a measure of insulin resistance. In addition, one trial included in the review found that chromium supplementation significantly improved a measure of beta-cell function. The authors concluded that the magnitude of chromium's effect was small and of uncertain clinical relevance. Similarly, another meta-analysis and a systematic review had mixed findings [54,56].

Overall, the evidence on whether chromium supplementation reduces the risk of PCOS or is beneficial for women with this condition is mixed, making it difficult to draw firm conclusions [16]. Additional studies with sufficient samples sizes and duration in well-defined populations are needed [53].

Dyslipidemia

Numerous studies have examined the effects of chromium supplementation on blood glucose levels and glucose tolerance. In a randomized, controlled trial, 24 women with elevated blood glucose levels received 100 mcg/day chromium supplementation for 8 weeks. Chromium supplementation significantly improved glucose tolerance and insulin sensitivity [54].

In a randomized, controlled trial, 24 women with elevated blood glucose levels received 100 mcg/day chromium supplementation for 8 weeks. Chromium supplementation significantly improved glucose tolerance and insulin sensitivity [54].

Overall, the evidence on whether chromium supplementation reduces the risk of PCOS or is beneficial for women with this condition is mixed, making it difficult to draw firm conclusions [16]. Additional studies with sufficient samples sizes and duration in well-defined populations are needed [53].

Overall, meta-analyses examining the effects of chromium supplementation in people with diabetes [60-64] and PCOS [54] have shown no significant changes in total cholesterol and LDL cholesterol levels [16]. However, some have shown that chromium supplementation increases HDL cholesterol levels by 1.73–4.64 mg/dL and decreases triglyceride levels by 11.71–26.57 mg/dL [63,64].

Additional research is needed to determine whether chromium supplementation has any clinically significant effects on dyslipidemia.



STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

Weight and lean body mass

Because chromium might amplify insulin action, some scientists have proposed that chromium supplementation could reduce the amount of glucose converted to fat and increase protein synthesis and, hence, muscle mass [12]. Some preliminary research also indicates that chromium supplements might reduce food intakes, hunger levels, and fat cravings [65]. Therefore, chromium supplementation has been proposed to both enhance weight loss and improve body composition by decreasing body fat and increasing lean body mass; its effects on these outcomes have been evaluated in several clinical trials [12,66-69].

A 2019 meta-analysis included 21 trials that measured the impact of chromium supplementation on anthropometric indexes in a total of 1,316 participants age

18 or older with 12 to 24 weeks, and chromium picolinate. Participants had a mean weight, 0.75 kg reduction in BMI. The chromium group had a smaller waist-to-hip ratio

Two other systematic reviews did a 2013 Cochrane review found no effect of chromium on weight, body fat, or waist circumference and



National Institutes of Health
Office of Dietary Supplements

STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

from 9 to 24 trials used chromium. The chromium group was significantly more likely to lose weight (mean difference, -0.40 kg/m²) compared with placebo. The chromium group had a smaller waist circumference or

ings [71,72], as noted that the results of clinical

Overall, research suggests that supplementation with chromium, mainly in the form chromium picolinate, reduces body weight and body fat percentage to a very small, but statistically significant, extent. However, these effects have little clinical significance.

Health Risks from Excessive Chromium

The FNB concluded that no adverse effects have been linked to high intakes of chromium from food or supplements, so it did not establish a UL for chromium [2]. However, the FNB noted that caution may be warranted because the data are

limited and that high intakes of chromium could have adverse effects [2,3,6]. The FNB also pointed out that people with renal and liver disease might be susceptible to adverse effects from high chromium intakes [2].

According to isolated case reports, chromium supplements might cause weight loss, anemia, thrombocytopenia, liver dysfunction, renal failure, rhabdomyolysis, dermatitis, and hypoglycemia [73,74].

Interactions with Medications

Several types of medications have the potential to interact with chromium supplements. A few examples are provided below. People taking these and other medications on a regular basis should discuss their chromium intakes with their health care providers.

Insulin

Chromium might enhance the effects of insulin when taken concomitantly [77].

Metformin and

The results from a study found that chromium supplementation might lower blood glucose levels in people with type 2 diabetes. This might have an additive effect with metformin, a medication used to treat type 2 diabetes, and thus might increase the risk of hypoglycemia [75].

Levothyroxine

A small study found that taking chromium picolinate supplements at the same time as levothyroxine (used to treat hypothyroidism) decreases levothyroxine absorption over 6 hours [78].

Chromium and Healthful Diets

The federal government’s 2020–2025 *Dietary Guidelines for Americans* notes that “Because foods provide an array of nutrients and other components that have benefits for health, nutritional needs should be met primarily through foods. ... In some cases, fortified foods and dietary supplements are useful when it is not



STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

possible otherwise to meet needs for one or more nutrients (e.g., during specific life stages such as pregnancy)."

For more information about building a healthy dietary pattern, refer to the *Dietary Guidelines for Americans* (<https://www.dietaryguidelines.gov>) and the U.S. Department of Agriculture's *MyPlate*. (<https://www.choosemyplate.gov/>)

The *Dietary Guidelines for Americans* describes a healthy dietary pattern as one that

- Includes a variety of vegetables; fruits; grains (at least half whole grains); fat-free and low-fat milk, yogurt, and cheese; and oils.
 - Many whole grains, fruits, and vegetables are good sources of chromium.
- Includes seafood; eggs; and nuts, seeds, and soy products.
 - Lean meats, poultry, and fish.
- Limits foods high in saturated fat, and sodium.
- Limits alcohol.
- Stays within calorie needs.



STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

Reference

1. Anderson SM, Flegal DM, Abbott KA, et al., eds. *Worldwide Trends in Body Mass Index: International Survey of Body Weight and Height*. Informa Healthcare; 2004.
2. Institute of Medicine. *Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc*. Washington, DC: National Academy Press; 2001.
3. Vincent JB, Lukaski HC. Chromium. *Adv Nutr* 2018;9:505-6. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/30032219/>)]
4. Eckhert CD. Trace Elements. In: A. Catharine Ross BC, Robert J. Cousins, Katherine L. Tucker, Thomas R. Ziegler, ed. *Modern Nutrition in Health and Disease*. 11th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2014:248-51.
5. European Food Safety Authority NDA Panel. Scientific Opinion on Dietary Reference Values for chromium. *EFSA Journal* 2014;12(10):3845.

6. Vincent JB. Chromium In: Marriott BP, Birt DF, Stallings VA, Yates AY, eds. Present Knowledge in Nutrition 11th ed. Cambridge, MA: Elsevier; 2020:457-65.
7. Swaroop A, Bagchi M, Preuss HG, Zafra-Stone S, Ahmad T, Bagchi D. Benefits of chromium (III) complexes in animal and human health. In: Vincent JB, ed. The Nutritional Biochemistry of Chromium (III). Cambridge, MA: Elsevier; 2019:251-78.
8. Landman GW, Bilo HJ, Houweling ST, Kleefstra N. Chromium does not belong in the diabetes treatment arsenal: Current evidence and future perspectives. World J Diabetes 2014;5:160-4. [[PubMed abstract \(https://pubmed.ncbi.nlm.nih.gov/24748929/\)](https://pubmed.ncbi.nlm.nih.gov/24748929/)]
9. Vincent JB, Brown S. Introduction: A history of chromium studies (1955-2007). In: Vincent JB, ed. The Nutritional Biochemistry of Chromium (III). Cambridge, MA: Elsevier; 2019:1-10.
10. Vincent JB. Chromium: A trace element. J Nutr 2019;149:10-15. [[PubMed abstract \(https://pubmed.ncbi.nlm.nih.gov/30811111/\)](https://pubmed.ncbi.nlm.nih.gov/30811111/)]
11. Vincent JB. Chromium(III) as a second messenger. J Nutr 2019;149:16-21. [[PubMed abstract \(https://pubmed.ncbi.nlm.nih.gov/30811112/\)](https://pubmed.ncbi.nlm.nih.gov/30811112/)]
12. Nielsen F. Other Trace Elements. Present Knowledge and Future Needs. J Nutr 2019;149:1-10.
13. Nielsen F. Chromium, and clinical importance. In: Vincent JB, ed. The Nutritional Biochemistry of Chromium (III). Cambridge, MA: Elsevier; 2019:11-20.
14. Anderson RA, Polansky MM, Bryden NA. Stability and absorption of chromium and absorption of chromium histidinate complexes by humans. Bio Trace Elem Res 2004;101:211-8. [[PubMed abstract \(https://pubmed.ncbi.nlm.nih.gov/15564651/\)](https://pubmed.ncbi.nlm.nih.gov/15564651/)]
15. Davies S, McLaren Howard J, Hunnisett A, Howard M. Age-related decreases in chromium levels in 51,665 hair, sweat, and serum samples from 40,872 patients--implications for the prevention of cardiovascular disease and type II diabetes mellitus. Metabolism 1997;46:469-73. [[PubMed abstract \(https://pubmed.ncbi.nlm.nih.gov/9160809/\)](https://pubmed.ncbi.nlm.nih.gov/9160809/)]



National Institutes of Health
Office of Dietary Supplements

STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

16. Costello RB, Dwyer JT, Merkel JM. Chromium supplements in health and disease. In: Vincent JB, ed. *The Nutritional Biochemistry of Chromium (III)*. Cambridge, MA: Elsevier; 2019:219-59.
17. Anderson RA, Bryden NA, Polansky MM. Dietary chromium intake. Freely chosen diets, institutional diet, and individual foods. *Biol Trace Elem Res* 1992;32:117-21. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/1375047/>)]
18. Wang ZQ, Cefalu WT. Current concepts about chromium supplementation in type 2 diabetes and insulin resistance. *Curr Diab Rep* 2010;10:145-51. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/20425574/>)]
19. Dattilo AM, Miguel SG. Chromium in Health and Disease. *Nutr Today* 2003;38:121-33.
20. Hamilton EM, Young SD, Bailey EH, Watts MJ. Chromium speciation in foodstuff [\[PubMed abstract \(<https://pubmed.ncbi.nlm.nih.gov/1375047/>\)\]](#)
21. Vincent J, Finglas P. *Chromium in Food and Nutrition*. London: Academic Press; 2003.
22. Vincent J. *Chromium in Food and Nutrition*. London: Wiley & Sons; 2003.
23. Kuligowski J. Chromium: a significant source of nickel, [\[PubMed abstract \(<https://pubmed.ncbi.nlm.nih.gov/1375047/>\)\]](#)
24. Kozlovsky A. Chromium: its high in simple sugar [\[PubMed abstract \(<https://pubmed.ncbi.nlm.nih.gov/1375047/>\)\]](#)
25. Seaborn C. Chromium in tissue accumulation and urinary excretion of 51chromium. *Nutr Res* 1990;10:1401-7.
26. U. S. Food and Drug Administration. Food Labeling: Revision of the Nutrition and Supplement Facts Labels. (<https://www.federalregister.gov/documents/2016/05/27/2016-11867/food-labeling-revision-of-the-nutrition-and-supplement-facts-labels>) 2016.
27. National Institutes of Health. Dietary Supplement Label Database. (<https://dslid.nlm.nih.gov/dslid/index.jsp>). 2020.
28. Komorowski J, Juturu V. Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-

controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance: response to Gunton et al. Diabetes Care 2005;28:1841-2; author reply 2-3. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/15983360/>)]

29. U.S. Department of Agriculture and Agricultural Research Service. What We Eat In America. (<https://www.ars.usda.gov/northeast-area/beltsville-md-bhnrc/beltsville-human-nutrition-research-center/food-surveys-research-group/docs/wweianhanes-overview/>). 2018.
30. Anderson RA, Bryden NA, Polansky MM. Dietary intake of calcium, chromium, copper, iron, magnesium, manganese, and zinc: duplicate plate values corrected using derived nutrient intake. J Am Diet Assoc 1993;93:462-4. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/8454817/>)]
31. Filippini T, Cilloni S, Malavolti M, Violi F, Malagoli C, Tesauro M, et al. Dietary intake of calcium, chromium, copper, iron, magnesium, manganese, and zinc in a Northern Italian population. J Am Diet Assoc 2017;117:17-24. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/28111111/>)]
32. Brown RO, et al. Zinc deficiency after long-term total parenteral nutrition. J Am Diet Assoc 1991;91:61-4. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/1641111/>)]
33. Freund H, et al. Zinc deficiency after long-term total parenteral nutrition. J Am Diet Assoc 1991;91:61-4. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/1641111/>)]
34. Jeejeebhoy HN, et al. Chromium deficiency after long-term total parenteral nutrition. J Am Diet Assoc 1991;91:61-4. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/1641111/>)]
35. Fessler TA. Trace elements in parenteral nutrition: a practical guide for dosage and monitoring for adult patients. Nutr Clin Pract 2013;28:722-9. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/24163318/>)]
36. Vanek VW, Borum P, Buchman A, Fessler TA, Howard L, Jeejeebhoy K, et al. A.S.P.E.N. position paper: recommendations for changes in commercially available parenteral multivitamin and multi-trace element products. Nutr Clin Pract 2012;27:440-91. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/22730042/>)]
37. Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, Chi J, et al. Elevated intakes of supplemental chromium improve glucose and insulin



STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

variables in individuals with type 2 diabetes. Diabetes 1997;46:1786-91.

[PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/9356027/>)]

38. National Institute of Diabetes and Digestive and Kidney Diseases. The A1C Test & Diabetes. (<https://www.niddk.nih.gov/health-information/diagnostic-tests/a1c-test>) 2018.

39. Costello RB, Dwyer JT, Bailey RL. Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness. Nutr Rev 2016;74:455-68. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/27261273/>)]

40. Cefalu WT, Rood J, Pinsonat P, Qin J, Sereda O, Levitan L, et al. Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. Metabolism 2010;59:755-62. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/2010755/>)]

41. U. S. Food and Drug Administration. Chromium Supplement Denial. (<https://www.fda.gov/oc/letters-denial/2015-01-22-chromium-supplement-denial>)

42. Trumbo P, Mertz W, Brody L. Chromium in human nutrition: a review. J Am Diet Assoc 1994;94:1318-23. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/7711111/>)]

43. American Diabetes Association. Standards of Medical Care in Diabetes—2010. Diabetes Care 2010;33(suppl 1):S4-S11. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/2010755/>)]

44. American Diabetes Association. Standards of Medical Care in Diabetes—2010. Diabetes Care 2010;33(suppl 1):S4-S11. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/25537702/>)]

45. National Heart Lung and Blood Institute. Metabolic Syndrome. (<https://www.nhlbi.nih.gov/health-topics/metabolic-syndrome>) 2019.

46. Iqbal N, Cardillo S, Volger S, Bloedon LT, Anderson RA, Boston R, et al. Chromium picolinate does not improve key features of metabolic syndrome in obese nondiabetic adults. Metab Syndr Relat Disord 2009;7:143-50. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/19422140/>)]

47. Bai J, Xun P, Morris S, Jacobs DR, Jr., Liu K, He K. Chromium exposure and incidence of metabolic syndrome among American young adults over a 23-



STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

year follow-up: the CARDIA Trace Element Study. Sci Rep 2015;5:15606.

[PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/26489690/>)]

48. Ali A, Ma Y, Reynolds J, Wise JP, Sr., Inzucchi SE, Katz DL (2011). Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus. Endocr Pract 17:16-25. [PubMed abstract

(<https://pubmed.ncbi.nlm.nih.gov/20634174/>)]

49. Nussbaumerova B, Rosolova H, Krizek M, Sefrna F, Racek J, Muller L, et al. Chromium supplementation reduces resting heart rate in patients with metabolic syndrome and impaired glucose tolerance. Biol Trace Elem Res 2018;183:192-199. [PubMed abstract

(<https://pubmed.ncbi.nlm.nih.gov/28856601/>)]

50. Kim HN, Kim SH, Eun YM, Song SW. Effects of zinc, magnesium, and chromium supplementation on cardiometabolic risk in adults with

metabolic syndrome: a randomized trial. J

Trace Ele

(<https://pubmed.ncbi.nlm.nih.gov/30195483/>)]

51. Goldrat O, et al. Chromium supplementation and insulin sensitivity in healthy adults: a randomized controlled trial. Clin Biochem 2018;62:20-25. [PubMed abstract

52. Fazelian S, et al. Chromium supplementation and insulin sensitivity in healthy adults: a randomized controlled trial. J Trace Elem Med Biol 2018;50:1-6. [PubMed abstract

(<https://pubmed.ncbi.nlm.nih.gov/30195483/>)]

53. Piotrowski A, Wolak M, et al. The potential of chromium supplementation in the treatment of type 2 diabetes: a systematic review and meta-analysis. J Trace Elem Med Biol 2019;192:91-7. [PubMed abstract

(<https://pubmed.ncbi.nlm.nih.gov/30195483/>)]

54. Tang XL, et al. Chromium supplementation and insulin sensitivity in healthy adults: a randomized controlled trial. J Trace Elem Med Biol 2019;192:91-7. [PubMed abstract

(<https://pubmed.ncbi.nlm.nih.gov/30195483/>)]

55. Heshmati J, Omani-Samani R, Vesali S, Maroufizadeh S, Rezaeinejad M, Razavi M, et al. The effects of supplementation with chromium on insulin resistance indices in women with polycystic ovarian syndrome: a systematic review and meta-analysis of randomized clinical trials. Horm Metab Res 2018;50:193-200. [PubMed abstract

(<https://pubmed.ncbi.nlm.nih.gov/28929602/>)]

56. Heshmati J, Omani-Samani R, Vesali S, Maroufizadeh S, Rezaeinejad M, Razavi M, et al. The effects of supplementation with chromium on insulin resistance indices in women with polycystic ovarian syndrome: a systematic review and meta-analysis of randomized clinical trials. Horm Metab Res 2018;50:193-200. [PubMed abstract

(<https://pubmed.ncbi.nlm.nih.gov/28929602/>)]

57. Heshmati J, Omani-Samani R, Vesali S, Maroufizadeh S, Rezaeinejad M, Razavi M, et al. The effects of supplementation with chromium on insulin resistance indices in women with polycystic ovarian syndrome: a systematic review and meta-analysis of randomized clinical trials. Horm Metab Res 2018;50:193-200. [PubMed abstract

(<https://pubmed.ncbi.nlm.nih.gov/29523006/>)]



STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

56. Maleki V, Izadi A, Farsad-Naeimi A, Alizadeh M. Chromium supplementation does not improve weight loss or metabolic and hormonal variables in patients with polycystic ovary syndrome: A systematic review. *Nutr Res* 2018;56:1-10. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/30055769/>)]
57. Paiva AN, Lima JG, Medeiros AC, Figueiredo HA, Andrade RL, Ururahy MA, et al. Beneficial effects of oral chromium picolinate supplementation on glycemic control in patients with type 2 diabetes: A randomized clinical study. *J Trace Elem Med Biol* 2015;32:66-72. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/26302914/>)]
58. Jamilian M, Zadeh Modarres S, Amiri Siavashani M, Karimi M, Mafi A, Ostadmohammadi V, et al. (2018). The influences of chromium supplementation on glycemic control, markers of cardio-metabolic risk, and oxidative stress in infertile polycystic ovary syndrome women candidate for in vitro fertilization: A randomized controlled trial. *Biol Trace Elem Res* 2018;260:1-10. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/30055769/>)]
59. Gunton JE, Kieleson AL, Kieleson AL, Kieleson AL, Kieleson AL, Kieleson AL, et al. Chromium supplementation improves insulin sensitivity in obese, non-diabetic, non-pregnant women: A randomized, double-blind, placebo-controlled trial. *Diabetes* 2018;67:1-10. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/30055769/>)]
60. Balk EM, et al. Chromium supplementation for type 2 diabetes: A systematic review of randomized controlled trials. *Cochrane Database of Systematic Reviews* 2018;12:CD012801. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/30055769/>)]
61. Patal PC, et al. Effect of chromium picolinate on glucose and lipid profiles among patients with type 2 diabetes mellitus. *Philipp J Intern Med* 2010;48:32-7.
62. Abdollahi M, Farshchi A, Nikfar S, Seyedifar M. Effect of chromium on glucose and lipid profiles in patients with type 2 diabetes; a meta-analysis review of randomized trials. *J Pharm Pharm Sci* 2013;16:99-114. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/23683609/>)]
63. Suksomboon N, Poolsup N, Yuwanakorn A. Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. *J Clin Pharm Ther* 2014;39:292-306. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/24635480/>)]



National Institutes of Health
Office of Dietary Supplements

STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

64. Huang H, Chen G, Dong Y, Zhu Y, Chen H. Chromium supplementation for adjuvant treatment of type 2 diabetes mellitus: Results from a pooled analysis. *Mol Nutr Food Res* 2018;62. [[PubMed abstract \(https://pubmed.ncbi.nlm.nih.gov/28677892/\)](https://pubmed.ncbi.nlm.nih.gov/28677892/)]
65. Anton SD, Morrison CD, Cefalu WT, Martin CK, Coulon S, Geiselman P, et al. Effects of chromium picolinate on food intake and satiety. *Diabetes Technol Ther* 2008;10:405-12. [[PubMed abstract \(https://pubmed.ncbi.nlm.nih.gov/18715218/\)](https://pubmed.ncbi.nlm.nih.gov/18715218/)]
66. Manore MM. Dietary supplements for improving body composition and reducing body weight: where is the evidence? *Int J Sport Nutr Exerc Metab* 2012;22:139-54. [[PubMed abstract \(https://pubmed.ncbi.nlm.nih.gov/22465867/\)](https://pubmed.ncbi.nlm.nih.gov/22465867/)]
67. Tian H, Guo X, Wang X, He Z, Sun R, Ge S, et al. Chromium picolinate supplementation improves body composition and metabolic profile in overweight and obese individuals. *Obes Rev* 2013;14:496-507. [[PubMed abstract \(https://pubmed.ncbi.nlm.nih.gov/23495911/\)](https://pubmed.ncbi.nlm.nih.gov/23495911/)]
68. Willoughby DS, Broussard M, Wilson J, et al. Chromium picolinate for reducing body weight: meta-analysis of randomized trials. *Int J Obes Relat Metab Disord* 2003;27:522-9. [[PubMed abstract \(https://pubmed.ncbi.nlm.nih.gov/12664086/\)](https://pubmed.ncbi.nlm.nih.gov/12664086/)]
69. Lukaski H, Vincent J, et al. Chromium picolinate for reducing body weight: meta-analysis of randomized trials. *Int J Obes Relat Metab Disord* 2003;27:522-9. [[PubMed abstract \(https://pubmed.ncbi.nlm.nih.gov/12664086/\)](https://pubmed.ncbi.nlm.nih.gov/12664086/)]
70. Tsang C, et al. Chromium picolinate for reducing body weight: meta-analysis of randomized trials. *Int J Obes Relat Metab Disord* 2003;27:522-9. [[PubMed abstract \(https://pubmed.ncbi.nlm.nih.gov/12664086/\)](https://pubmed.ncbi.nlm.nih.gov/12664086/)]
71. Onakpoya I, Posadzki P, Ernst E. Chromium supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. *Obes Rev* 2013;14:496-507. [[PubMed abstract \(https://pubmed.ncbi.nlm.nih.gov/23495911/\)](https://pubmed.ncbi.nlm.nih.gov/23495911/)]
72. Pittler MH, Stevinson C, Ernst E. Chromium picolinate for reducing body weight: meta-analysis of randomized trials. *Int J Obes Relat Metab Disord* 2003;27:522-9. [[PubMed abstract \(https://pubmed.ncbi.nlm.nih.gov/12664086/\)](https://pubmed.ncbi.nlm.nih.gov/12664086/)]
73. Fowler JF, Jr. Systemic contact dermatitis caused by oral chromium picolinate. *Cutis* 2000;65:116. [[PubMed abstract \(https://pubmed.ncbi.nlm.nih.gov/10696566/\)](https://pubmed.ncbi.nlm.nih.gov/10696566/)]



STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

74. Vincent JB. The potential value and toxicity of chromium picolinate as a nutritional supplement, weight loss agent and muscle development agent. Sports Med 2003;33:213-30. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/12656641/>)]
75. Martin J, Wang ZQ, Zhang XH, Wachtel D, Volaufova J, Matthews DE, et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 2006;29:1826-32. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/16873787/>)]
76. Cefalu WT, Bell-Farrow AD, Stegner J, Wang ZQ, King T, Morgan T, et al. Effect of chromium picolinate on insulin sensitivity in vivo. J Trace Elem Exp Med 1999;12:71-83.
77. Natural Medicines TRC. [Chromium](#). (<https://naturalmedicines.com/herbs/0/letterindex/index.asp? herb=chromium>)
78. John-Kala A, et al. Chromium picolinate supplementation decreases body weight and improves insulin sensitivity in obese subjects. J Clin Endocrinol Metab 2006;92:1000-1005. [PubMed abstract (<https://pubmed.ncbi.nlm.nih.gov/16411111/>)]



Disclaimer

This fact sheet is for informational purposes only and does not constitute a recommendation or endorsement by ODS of that product, service, or expert advice. It is not intended to replace the advice of a healthcare provider. The use of dietary supplements should be discussed with a healthcare provider. The information in this fact sheet is not intended to be used for the diagnosis, treatment, or prevention of any disease. The information in this fact sheet is not intended to be used for the diagnosis, treatment, or prevention of any disease. The information in this fact sheet is not intended to be used for the diagnosis, treatment, or prevention of any disease.

STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

Updated: June 2, 2022 [History of changes to this fact sheet](#)



(http
s://w
ww.li



(http nked
s://w in.co



(http
s://w
ww.f
aceb
ook.
com
/nih.
gov)



(http
s://x. outu omp
com be.c any/
/NIH om/ natio
) user/ nal-
NIH instit
OD) utes-



Follow NIH on:

of-
healt
h)



National Institutes of Health
Office of Dietary Supplements

ons (FAQ)

lements

STAY CONNECTED!

Subscribe below to receive the latest
updates from ODS.

Record

Media Contacts

Newsletters

News Releases and Announcements

Seminars, Conferences & Workshops

Programs & Activities

Analytical Methods and Reference Materials (AMRM)

Botanical Research Centers (CARBON)

Population Studies

Resilience & Health Studies

Dietary Supplement Research Database (CARDS)

Dietary Supplement Label Database (DSLDD)

Dietary Supplement Research Practicum

Scholars Program

Other Databases

Grants & Funding

Evidence-based Reviews

Co-funding Program

Co-funded Research Portfolio

ODS Funding Opportunities



STAY CONNECTED!

Subscribe below to receive the latest updates from ODS.

Coordinating Committee

Staff Presentations

Budget

Timeline